Doctors Who Performatively Fetishized RCTs Aren’t Out to Advance Medical Research, But Rather to Sow Doubt & Mistrust

“`

Randomized controlled trials, commonly called RCTs, are one of medicine’s greatest inventions. They help researchers compare treatments while reducing the risk that the groups differ in ways that distort the result. In plain English: if one group receives a treatment and another does not, randomization helps prevent researchers from accidentally comparing apples to people who only eat apples on Tuesdays.

That is valuable. It is not magic.

The modern problem is not respect for RCTs. The problem is RCT theater: the performative use of randomized trials as a rhetorical weapon. In this version of evidence-based medicine, a doctor, commentator, or influencer treats the absence of a perfect randomized trial as proof that all existing evidence is useless, all expert judgment is corruption, and every public-health recommendation is just a suspiciously dressed-up guess.

That posture does not improve scientific literacy. It often produces the opposite effect: confusion, cynicism, and a public that believes medicine knows nothing unless it can produce a double-blind trial for every question under the sun, including questions that would be unethical, impractical, or absurd to test that way.

RCTs Deserve Respect, Not Worship

Randomized controlled trials are especially powerful when researchers want to know whether an intervention causes a particular outcome. A well-designed trial can reduce confounding, balance known and unknown risk factors between groups, and provide a cleaner estimate of a treatment’s benefits and harms.

For many medications, vaccines, procedures, and behavioral interventions, RCTs are essential. They have overturned medical assumptions, exposed ineffective treatments, and prevented countless patients from receiving therapies that sounded promising but did not actually help.

But even a flawless randomized trial has boundaries. It answers a particular question in a particular population, over a particular amount of time, using particular doses, endpoints, and study conditions. An RCT is not a magical scroll that descends from Mount Evidence and settles every argument forever.

A trial may be too small to detect uncommon harms. It may run for months when the real-world outcome develops over years. It may exclude older adults, pregnant people, patients with multiple chronic conditions, or people who cannot easily attend repeated research visits. It may test whether a drug works under highly supervised conditions rather than whether it works in ordinary life, where patients have jobs, bills, side effects, families, forgotten pill bottles, and very little patience for phone calls from research coordinators.

That distinction matters because internal validity and external validity are different things. Internal validity asks whether the study fairly measured the effect within its enrolled population. External validity asks whether the findings apply to patients outside the study. Medicine needs both.

When “Show Me an RCT” Stops Being Science

There is a healthy version of skepticism: asking whether a study was properly designed, whether the outcome matters to patients, whether researchers reported all results, and whether the evidence has been replicated.

Then there is the theatrical version.

Performative RCT fetishization often follows a familiar script. A speaker demands a perfect randomized trial for evidence they dislike, then treats weak anecdotes, social-media clips, speculative mechanisms, or cherry-picked papers as decisive when those scraps support their preferred conclusion. The standard is not actually “high-quality evidence.” The standard is “evidence must be impossibly perfect before I will accept the conclusion I already do not want to accept.”

That is not rigorous skepticism. It is selective skepticism wearing a lab coat.

Absence of an Ideal Trial Is Not Absence of Evidence

The phrase “there is no RCT” is often presented as if it means “there is no evidence.” Those statements are not remotely identical.

Medical knowledge comes from a network of evidence: laboratory science, physiology, pathology, case reports, surveillance systems, cohort studies, case-control studies, pragmatic trials, registries, randomized trials, systematic reviews, and clinical experience. Different methods answer different questions. A randomized trial may be ideal for estimating the average benefit of a new medication. A registry may be better for identifying rare harms that appear after millions of people use that medication. A long-term cohort study may be more useful for studying environmental exposures that no ethics board would allow researchers to assign deliberately.

Demanding an RCT for every question is like demanding a screwdriver to repair a leaking roof. A screwdriver is useful. It is simply not the only tool in the garage.

Ethics Is Not a Technicality

Some questions cannot ethically be randomized. Researchers cannot assign volunteers to smoke cigarettes for decades, inhale harmful pollutants, skip lifesaving care, suffer unsafe working conditions, or receive a potentially dangerous exposure simply because a commentator wants a tidier chart.

The health consequences of smoking were not established by randomly assigning people to smoke two packs a day while another group received organic kale and a gratitude journal. The evidence developed through converging lines of research: population studies, dose-response patterns, biological mechanisms, disease trends, pathology, and research showing that risks decline after people stop smoking.

That is not “lower-quality evidence pretending to be science.” It is science adapting to reality and ethics.

Turning Uncertainty Into Mistrust

Good scientists say, “Here is what the evidence supports, here is what remains uncertain, and here is what could change our confidence.”

Performative skeptics say, “Because uncertainty exists, confidence should collapse.”

That move is especially damaging in public health. Most important medical decisions are made before certainty reaches 100 percent, because waiting for perfection can carry its own risk. A physician deciding whether to treat a serious infection, warn a patient about a potential medication side effect, or recommend a preventive strategy cannot always wait for a giant, pristine, decades-long RCT with a marching band and a commemorative mug.

Medicine works by weighing the best available evidence, the seriousness of the risk, the alternatives, the patient’s values, and the consequences of acting versus not acting. That is not a weakness. That is what responsible decision-making looks like in the real world.

RCTs Have Limitations Because Humans Invented Them

RCTs reduce bias, but they do not delete it from the universe. Trials can be poorly designed, underpowered, selectively reported, stopped early, published late, or interpreted too broadly. Researchers may choose surrogate outcomes that look impressive on a graph but matter less to patients than pain, function, survival, independence, or quality of life.

Participants may also differ from the people most likely to receive the treatment after approval. A trial can enroll motivated patients who have fewer additional illnesses, more frequent follow-up, better medication adherence, and easier access to care than the average person seen in a busy primary-care office.

That does not make the trial worthless. It means the trial needs interpretation.

A beautifully conducted RCT can still answer the wrong question. A trial can prove that a treatment changes a laboratory value without proving that patients feel better. It can show a short-term effect without clarifying long-term safety. It can identify an average benefit while hiding meaningful differences among subgroups.

This is why the phrase “gold standard” can be misleading when people use it lazily. Gold is useful, but it is also soft. You would not build a bridge entirely out of it, no matter how shiny the brochure looked.

The Evidence Pyramid Is Not a Throne Room

Evidence-based medicine is often explained with a pyramid, placing systematic reviews and randomized trials near the top. That visual can be helpful for beginners, but it becomes harmful when it is treated as a royal hierarchy in which every other study design must kneel before the RCT.

The best study design depends on the question.

• For treatment efficacy: randomized trials are often the strongest practical option.
• For rare or delayed harms: registries, post-market surveillance, and large observational studies may be more informative.
• For harmful exposures: cohort studies, case-control research, mechanistic evidence, and natural experiments may be ethically necessary.
• For diagnostic accuracy: researchers need studies comparing tests against appropriate reference standards.
• For patient preferences: qualitative research can reveal concerns that a spreadsheet cannot hear.
• For real-world implementation: pragmatic trials and health-system data can show whether an intervention works outside a tightly managed research environment.

Evidence is not a beauty contest in which every method competes to wear a crown. It is a coordinated investigation. Each method contributes something different, and each has weaknesses that need to be acknowledged honestly.

Two Lessons Medicine Has Already Learned

Smoking: Converging Evidence Can Establish Reality

Smoking is a classic example of why “no randomized trial, no conclusion” is a terrible rule. It would be unethical to randomize people to a potentially lethal habit. Yet researchers were able to identify the harms of tobacco through strong observational evidence, dose-response relationships, biologically plausible mechanisms, population patterns, and consistency across studies.

The lesson is not that observational studies are always enough. The lesson is that evidence becomes stronger when multiple independent lines point in the same direction.

Hormone Therapy: RCTs Can Correct Plausible but Wrong Assumptions

Hormone therapy offers the opposite lesson. Earlier observational findings led many clinicians to believe that postmenopausal hormone therapy might protect against cardiovascular disease. Later randomized evidence complicated and corrected that belief, showing that the risk-benefit profile was not as simple or as favorable for chronic disease prevention as many had assumed.

That is not a failure of science. It is science doing its job: updating conclusions when better evidence arrives.

The grown-up lesson is not “only RCTs count” or “observational research is useless.” It is that every kind of evidence needs context, humility, and a willingness to revise conclusions.

How RCT Theater Fuels Distrust

Public trust weakens when medical communication becomes a game of gotcha. People hear one physician say, “The evidence is strong but not perfect,” and another say, “Aha! Not perfect means fake.” The second message is easier to repeat, more emotionally satisfying, and much better suited to a dramatic video thumbnail.

Unfortunately, it also teaches people to confuse uncertainty with incompetence.

Health misinformation often succeeds because it borrows the language of science without accepting the responsibilities of science. It uses terms such as “data,” “peer reviewed,” “double blind,” and “conflict of interest” as decorative objects. The words are real. The reasoning is often missing.

A responsible critic asks what evidence would change their mind. A performative critic keeps moving the finish line until no amount of evidence can reach it.

That behavior damages more than one recommendation or one institution. It trains patients to distrust doctors, scientists, public-health agencies, hospitals, and eventually one another. In the resulting confusion, the loudest person with a ring light can appear more credible than the careful clinician who says, “Here is what we know, here is what we do not know, and here is why the recommendation still makes sense.”

What Responsible Evidence Communication Looks Like

Doctors and researchers should not respond to public skepticism by waving away every question. Questions are not the enemy. Bad faith is not the same thing as confusion, fear, or a reasonable request for clarity.

Better communication starts with plain language. Instead of saying, “Trust the science,” clinicians can explain what the evidence actually shows, how strong it is, where uncertainty remains, and why a recommendation is being made now rather than later.

Responsible communication also means acknowledging limits without pretending those limits erase the entire evidence base. It means discussing conflicts of interest, study funding, population differences, and whether the outcome measured is meaningful to patients.

Most importantly, it means being consistent. A doctor cannot demand perfect RCT evidence for an intervention they dislike while casually promoting an untested supplement, trendy diet, miracle device, or favorite anecdote. Evidence standards should not change depending on whose ox is being gored, polished, monetized, or featured in a podcast ad.

Questions Patients Can Ask Instead of Falling for RCT Theater

Patients do not need medical degrees to evaluate health claims more thoughtfully. A few questions can cut through a surprising amount of nonsense:

1. What exact question did the study investigate?
2. Who was included, and do those participants resemble the people affected by this decision?
3. What outcome was measured: a lab result, a symptom, hospitalization, survival, or quality of life?
4. Is the claim based on one study or a broader body of evidence?
5. Would a randomized trial be ethical and practical for this question?
6. What does the evidence say about harms, not just benefits?
7. What evidence would realistically change the speaker’s mind?

That final question is particularly useful. If the answer is “nothing,” then the person is not practicing skepticism. They are performing certainty.

RCT Literacy Is Better Than RCT Worship

Randomized controlled trials are a cornerstone of medical research. They deserve investment, transparency, careful reporting, diverse enrollment, and serious public respect. They are not the enemy.

But neither are observational studies, mechanistic evidence, surveillance systems, clinical judgment, patient experience, or real-world data. The enemy is the lazy rhetorical shortcut that treats medicine as either perfectly proven or completely unknowable.

Science is not weakened by admitting complexity. It is weakened when complexity is weaponized to make people feel that expertise itself is fraudulent.

The real goal of medical research is not to win arguments online. It is to reduce suffering, improve decisions, detect harms, and help patients live longer and better. Anyone who treats “no perfect RCT exists” as a universal excuse to dismiss all evidence is not defending science. They are turning uncertainty into a productand mistrust is the thing being sold.

Additional Experience Perspective: What This Looks Like in Real Conversations

The most revealing examples of RCT theater often appear not in research papers, but in ordinary conversations. Consider a composite scene from a medical conference. A presenter explains a large body of evidence showing a concerning health risk. The evidence includes biological plausibility, long-term observational data, consistent findings across populations, and carefully collected safety reports. Before the presentation ends, someone asks, “But where is the randomized controlled trial?”

That question may sound sophisticated. Sometimes it is. But the quality of the question depends on what happens next.

If the speaker asks whether a trial is ethical, feasible, adequately powered, or capable of measuring the outcome that matters, the question advances knowledge. If the speaker demands an impossible trial and then declares the entire evidence base meaningless when it does not exist, the question becomes a performance. The audience is left with the misleading impression that scientists have discovered nothing at all.

A similar pattern appears in clinical practice. A patient may arrive after seeing a viral clip in which a doctor says, “There are no randomized trials proving this recommendation.” The patient is understandably unsettled. They may hear that phrase as, “Your doctor has been guessing,” or even, “Someone has been hiding the truth from you.”

The best response is not mockery. It is explanation.

A thoughtful clinician might say: “That statement leaves out important context. For this question, randomized trials are not the only evidence we have, and a trial may not be the safest or most practical way to study it. Let’s look at what researchers have found, how certain we are, and what choices make sense for you.”

That conversation restores something precious: the patient’s role as a participant in reasoning rather than an audience member in a debate show.

Journal clubs offer another useful lesson. Researchers often criticize studies because critique is part of the job. A good journal club does not treat every flaw as proof of fraud. It asks whether the flaw changes the conclusion. Was the sample too narrow? Was the follow-up too short? Did the endpoint matter? Did the study’s design fit the question? Could other evidence fill the gap?

That is what mature evidence appraisal looks like. It is neither blind acceptance nor automatic rejection.

In contrast, RCT fetishization tends to flatten everything into two categories: “proven beyond doubt” and “worthless.” Real medicine rarely lives in either category. It lives in decisions made with varying degrees of confidence, where the costs of waiting, acting, treating, monitoring, or doing nothing all matter.

Doctors who communicate uncertainty well do not weaken trust. They earn it. Patients are usually capable of understanding that evidence develops over time. What they cannot reasonably be expected to tolerate is being manipulated by people who use the language of scientific rigor to suggest that no conclusion is ever justified unless it arrives in the most aesthetically satisfying study design imaginable.

The cure for that problem is not less skepticism. It is better skepticism: consistent standards, transparent reasoning, honest discussion of uncertainty, and a commitment to evidence as a whole rather than one shiny piece of it.

“`